What is Neurocrine Biosciences's license — revenue?

Neurocrine Biosciences (NBIX) reported license — revenue of $15M in Q2 2021.

What does license — revenue mean?

Income earned by granting other companies the right to use the firm's intellectual property or drug candidates.

Discontinued — last reported Q2 '21

Products & Services · Revenue

License — Revenue

Analysis

StatementSegment

CategoryProfitability

SignalHigher is better

VolatilityModerate

First reportedQ1 2020

Last reportedQ2 2021Nov 1, 2021

Rolls up toTotal Revenue

How to read this metric

An increase indicates successful commercialization or development progress by partners, whereas a decrease may signal a shift in strategy or the maturity of existing licensing agreements.

Detailed definition

This metric captures the revenue recognized from licensing intellectual property, technology, or drug candidates to thir...

Peer comparison

Standard across the pharmaceutical industry for companies that utilize partnership models to offset R&D costs and share commercialization risks.

Metric ID: nbix_segment_license_revenues

Historical Data

1 periods

	Q2 '21
Value	$15M

Similar Metrics at Other Companies

Roivant SciencesROIV View metric

InsmedINSM View metric

Roivant SciencesROIV View metric

Natera, Inc.NTRA View metric

ModernaMRNA View metric

Frequently Asked Questions

What is Neurocrine Biosciences's license — revenue?: Neurocrine Biosciences (NBIX) reported license — revenue of $15M in Q2 2021.
What does license — revenue mean?: Income earned by granting other companies the right to use the firm's intellectual property or drug candidates.